Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

Pharma gets social: How top pharma use Twitter in corporate ...

Starting off his series again in the New Year, Daniel Ghinn takes a look at the top 15 pharma companies’ use of social media site, Twitter. While Twitter is now well established among social media channels used by pharmaceutical companies, there is still...

Articles

Making digital an integral part of medical communications: l...

In our medical communications themed month, Dr Candice O’Sullivan explores concepts that can be borrowed from clinical practice to integrate digital into medical communications. The practice of medicine is not static, it is a fluid and evolving discipline. Prescribing new drugs, learning new procedures and applying new...

Articles

Defining patient populations is a key trend shaping the phar...

In order for the pharma industry to be successful, it must understand patient populations for specific diseases, says Christopher Ehinger. Do you agree? The pharmaceutical industry is in a state of evolution. Many blockbuster drugs that have supported the...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital